Vimarsana
Biggest News Aggregation in the World

Page 5 - Nextcell Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nextcell Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nextcell Pharma Today - Breaking & Trending Today

Diabetes Pipeline Landscape Guide 2021: Key Collaborations, Recent Trends, Emerging Drugs, Novel Technologies - Vimarsana News

Diabetes Pipeline Landscape Guide 2021: Key Collaborations, Recent Trends, Emerging Drugs, Novel Technologies

/PRNewswire/ -- The "Diabetes - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive...

Diabetes Pipeline Landscape Guide 2021: Key Collaborations, Recent Trends, Emerging Drugs, Novel Technologies - Vimarsana News

Diabetes Pipeline Landscape Guide 2021: Key Collaborations, Recent Trends, Emerging Drugs, Novel Technologies

/PRNewswire/ -- The "Diabetes - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive...

Diamyd Phase IIb trial results published in Diabetes Care - Vimarsana News

Diamyd Phase IIb trial results published in Diabetes Care

Diamyd Phase IIb trial results published in Diabetes Care STOCKHOLM, May 21, 2021 /PRNewswire/ -- Diabetes Care has published the results of DIAGNODE-2, a Phase IIb trial that evaluated intralymphatic administration of Diamyd Medical's lead drug candidate Diamyd (GAD-alum) in individuals recently diagnosed with type 1 diabetes. Results showed, in line with a published large-scale metaanalysis of clinical data, that while no treatment benefit was seen in the full patient population, three intralymphatic injections of Diamyd had a significant and positive effect on the preservation of insulin...

Diamyd® Phase IIb trial results published in Diabetes Care - Vimarsana News

Diamyd® Phase IIb trial results published in Diabetes Care

Diamyd® Phase IIb trial results published in Diabetes Care News provided by Share this article STOCKHOLM, May 21, 2021 /PRNewswire/ -- Diabetes Care has published the results of DIAGNODE-2, a Phase IIb trial that evaluated intralymphatic administration of Diamyd Medical's lead drug candidate Diamyd ® (GAD-alum) in individuals recently diagnosed with type 1 diabetes. Results showed, in line with a published large-scale metaanalysis of clinical data, that while no treatment benefit was seen in the full patient population, three intralymphatic injections of Diamyd ® had a significant and po...

Diamyd Medical contracts global CRO for Phase III trial with the diabetes vaccine Diamyd - Vimarsana News

Diamyd Medical contracts global CRO for Phase III trial with the diabetes vaccine Diamyd

Diamyd Medical contracts global CRO for Phase III trial with the diabetes vaccine Diamyd STOCKHOLM, April 15, 2021 /PRNewswire/ -- Diamyd Medical has contracted the global contract research organization (CRO) ICON plc for DIAGNODE-3, a placebo-controlled Phase III precision medicine trial with the diabetes vaccine Diamyd . The trial is designed to confirm the efficacy and safety of Diamyd in individuals recently diagnosed with type 1 diabetes who carry the genetically defined haplotype HLA DR3-DQ2. The trial is expected to begin recruiting patients later this year. "We have gotten to know ...